Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management?
- 1 February 2021
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 160 (3) , 649-651
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- GlaxoSmithKline foundation
- Pfizer
- GlaxoSmithKline
This publication has 15 references indexed in Scilit:
- Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incompleteUDCAresponse may improve outcomesAlimentary Pharmacology & Therapeutics, 2015
- A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and DyslipidemiaAmerican Journal of Gastroenterology, 2015
- Novel therapeutic targets in primary biliary cirrhosisNature Reviews Gastroenterology & Hepatology, 2015
- Unmet clinical need in autoimmune liver diseasesJournal of Hepatology, 2015
- Impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national studyHepatology, 2013
- Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic AcidGastroenterology, 2013
- The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated PruritusAmerican Journal of Gastroenterology, 2007
- Effects of long-term rifampicin administration in primary biliary cirrhosisGastroenterology, 1992
- Treatment of pruritus in primary biliary cirrhosis with rifampinGastroenterology, 1988
- Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasisGastroenterology, 1966